The agency previously declined to approve Atara's first Ebvallo biologics license application, but has accepted a data package it resubmitted this month.

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline growth drivers.

The firm will retain rights to its preclinical assets including two T-cell receptor T-cell therapies and its allogenic program.